Abstract:OBJECTIVE:To investigate the predictive value of prostate-specific antigen (PSA) and Gleason sum for results of radionuclide bone scintigraphy in prostate cancer patients, in order to determine when to perform a radionuclide bone scintigraphy in Chinese patients with newly diagnosed prostate cancer. METHODS:We retrospectively reviewed the charts of 624 consecutive patients with a pathology diagnosis of prostate cancer hospitalized in Department of Urology, Peking University First Hospital between Jan. 1994 and Dec. 2005, and evaluated the relationships between results of bone scintigraphy and serum tPSA, and between bone scintigraphy and Gleason sum. The receiver operating characteristics (ROC) curves were analyzed to determine the cut-off values of tPSA and Gleason sum for predicting positive results of bone scintigraphy. RESULTS:In the study, 443 patients underwent both a radionuclide bone scan and a serum PSA test prior to treatment, of whom, 216 (48.8%) got positive results, and 338 also possessed the Gleason sum for pathological evaluation. The serum tPSA levels were significantly higher in patients with positive results of the bone scan ( median: 71.00 μg/L; range: 1.30-2 400.00 μg/L) than those with negative results ( median: 60.00 μg/L; range: 0.60-201.00 μg/L; rank P<0.001), and the Gleason sums were also significantly higher in positive-bone-scan patients than in negative-bone-scan patients (7.7±1.5 vs. 6.7±1.8, P<0.001). Linear regression analysis suggested significant positive correlation between the results of the bone scan and the two afore-mentioned parameters, respectively (lg[PSA]: r=0.933, B=0.352, P=0.001; Gleason sum: r=0.971, B=0.096, P<0.001). The incidence of a positive bone scan result was 9.0% in patients with tPSA<10 μg/L and 3.8% in patients with Gleason sum<5. When the indication for bone scan was established as tPSA>15 μg/L or Gleason sum≥7,its sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy for positive results were 97.5%, 24.7%, 54.4%, 91.5% and 60.0%, respectively. CONCLUSION:In patients with prostate cancer, their positive results of the bone scan are significantly positively correlated to their higher PSA levels and higher Gleason sums, respectively. Our analyses suggest that a patient with newly diagnosed prostate cancer would not need to undergo radionuclide bone scintigraphy when the PSA level is lower than 10 μg/L and Gleason sum is less than 5, and that a prostate cancer patient with tPSA>15 μ g/L or Gleason sum≥7 should take a bone scintigraphy.

Bone marrow prostate specific antigen in diagnosis of prostatic cancer bone metastasis

The value of combined detection of PCA3 mRNA and PSA mRNA in peripheral blood of patients with prostate cancer

The Progress of Biomarkers in Prostate Cancer

Diagnostic value comparison of PSAM and PSAMR on PSA grey zone in prostate cancer by ROC curve analysis

The value of the ratio of transmembrane protease serine 2 and ETS-related gene fusion transcripts in the diagnosis of prostate cancer

The Application of Radionuclide Bone Scintigraphy,Serum PSA and ALP Measurement in Diagnosis of Bone Metastasis in Prostate Cancer Patients

Clinical Significance of PSA and ECT in Diagnosis of Prostate Cancer with Bone Metastasis

Applied Research of Prostate Specific Antigen Combined with Prostate Cancer Gene 3 in Diagnosis of Prostate Disease

Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction

Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases

Association between 99mTc-PSMA SPECT/CT imaging and prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels post-endocrine therapy in patients with prostate cancer and bone metastases

Technetium-99m-methylene diphosphonate single photon emission computed tomography/computed tomography combined with prostate-specific antigen/free prostate-specific antigen ratio for bone metastasis of prostate cancer

Clinical Diagnosis of Bone Metastasis from Prostate Cancer:Comparison of MRI and Bone Scintigraphy

Value of Multi-Biomarkers Plus PSA in the Diagnosis of Prostate Cancer

Clinical Analysis of Prostate Cancer with Bone Metastasis: A Report of 63 Cases

Predictive Value of Prostate-Specific Antigen and Gleason Sum for Results of Radionuclide Bone Scintigraphy in Patients with Prostate Cancer

Can bone scan be spared in asymptomatic prostate cancer patients at the initial stage of diagnosis?

The diagnostic significance of tiyeⅠcollagen-cross-linked N telopeptide in bone metastasis of prostate cancer

Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial

The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review

The Predictive Value of Prostate Specific Antigen Transition Zone Density in Prostate Biopsy